Back to search
FDAFDA · Food and drugs·Recall number Z-2473-2023

Atellica CH Gamma-Glutamyl Transferase-IIn vitro diagnostic use in the quantitative determination of gamma-glutamyl transferase in human serum and plasma (lithium heparin Test Code: GGT Siemens Material Number (SMN): 11097597

Published September 6, 2023 · Recall initiated: July 10, 2023

Summary

FDA records medical device Class II recall Z-2473-2023, published September 6, 2023 and initiated July 10, 2023. Recalling firm: Siemens Healthcare Diagnostics, Inc.; Status: Ongoing; Reported quantity: 19544 units; Lot: Unique Device Identification (UDI): 00630414596440 All Lot Numbers. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Potential for reagent carryover on the Atellica CH 930 resulting in a positive bias that could impact quality control (QC), patient samples, and calibrator results with from Atellica®CH Total Bilirubin_2 (TBil_2), Atellica® CH LDL Cholesterol (LDLC), Atellica® CH Gamma-Glutamyl Transferase (GGT) and Atellica® CH HDL Cholesterol (HDLC)

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Siemens Healthcare Diagnostics, Inc.
Distributor
US Nationwide - Worldwide Distribution Foreign: Taiwan Uruguay Vietnam
Lot
Unique Device Identification (UDI): 00630414596440 All Lot Numbers
Risk classification
Class II
Area (FDA)
device
Country
United States

Related recalls

Questions about this recall

Was Atellica CH Gamma-Glutamyl Transferase-IIn vitro diagnostic use in the quantitative determination of gamma-glutamyl transferase in human serum and plasma (lithium heparin Test Code: GGT Siemens Material Number (SMN): 11097597 recalled?

Yes. FDA published recall Z-2473-2023 on September 6, 2023. Reported hazard: Potential for reagent carryover on the Atellica CH 930 resulting in a positive bias that could impact quality control (QC), patient samples, and calibrator results with from Atellica®CH Total Bilirubin_2 (TBil_2), Atellica® CH LDL Cholesterol (LDLC), Atellica® CH Gamma-Glutamyl Transferase (GGT) and Atellica® CH HDL Cholesterol (HDLC)

What should I do if I have this product?

Voluntary: Firm initiated · Letter